Pittsburgh, PA, January 5th, 2022– BioHybrid Solutions™ (BHS) is pleased to announce the appointment of Jean Pineault as its new President and Chief Executive Officer effective immediately. Jean, brings a wealth of leadership, experience, and passion to BHS, specializing in growing and professionalizing privately held businesses in the biotechnology, pharmaceutical, and clinical diagnostics markets and positioning them for rapid and successful growth. Jean will succeed former President and CEO Dr. Alan Russell, who is one of the original founders and will remain engaged with the company in various advisory roles.
“Jean’s energy, passion, and a rare combination of scientific, commercial and operational expertise will accelerate BHS’s transformation into being the bioconjugation leader,” said Dr. Alan Russell, BHS original founder and former President and CEO. “We expect that our technology will significantly expand the therapeutic windows of a large number of biotherapeutics, allowing for much needed biologics based therapies to be deployed to a larger population of patients in need.”
Jean comes to BHS from his role as President and CEO of Haematologic Technologies, a marquee protein expert, clinical diagnostics reagents manufacturer, and large molecule contract research organization, where he identified and commercialized an orthogonal approach to Host Cell Proteins (HCP) mitigation. Earlier, as President and Chief Operating Officer of Pyxant Labs, a high-end bioanalytical laboratory, he accelerated growth by revamping laboratory and commercial operations, adding differentiated services and recruiting exceptional talent. Prior to Pyxant, as President of SPEware Corporation, a developer and manufacturer of advanced sample preparation solutions, Jean conceptualized the strategic growth strategy and acquisition blueprint resulting in a significant increase in valuation. He earned his Master of Science degree in Biochemistry and Molecular Biology and a Bachelor of Science degree in Biotechnology from the University of Ottawa.
“I am excited at the opportunity and privilege to accept the position of President and CEO of BHS, and to lead such a great company,” says Pineault. “While BHS technology can be applied to several industry verticals, biologics drug development is of particular interest. Driven by patients’ needs for better medical outcomes, high costs of biotherapeutics development failures, and increasingly stringent regulatory requirements, the industry players are hungry for improving and de-risking their biological drug development programs. The world-renowned scientists of BHS provide leading-edge, patented controlled polymerization technology poised to increasingly address these needs both as a service and drug development organization.”
Pineault’s appointment concludes a five month national search process completed by a search committee, led by Colaizzi, Chairman of the Board of Directors. “It was evident to the committee almost immediately that Jean’s strong track record of success overseeing all aspects of operational activity, along with his business acumen, would align very well with the work of BHS.”
About BioHybrid Solutions, LLC
BioHybrid Solutions™ (BHS), is a transformational platform technology company that develops next-generation NanoArmored™ protein-polymer conjugates. Using proprietary technology originally developed at Carnegie Mellon University, proteins are rationally and precisely modified with polymers to dramatically improve their stability and performance. The NanoArmor® platform technology can be applied across the $150 billion biocatalysis and therapeutics marketplace. NanoArmor® technology can dramatically improve processes, resulting in higher throughput, less waste, and lower costs. In addition, this technology can also open new routes of administration (such as, injectable to oral), improve pharmacokinetics, and reduce immunogenicity. BHS is developing the foundation through which any biotherapeutic can be NanoArmored™ to provide cost-effective solutions across industries. Visit us at www.biohybridsolutions.com
Please direct your inquiries to:
Megan Kemmerer
info@biohybridsolutions.com
More Company News
Myris Therapeutics is Developing Ultra-High DAR ADCs to Enable Novel Precision Medicine Treatments for Cancer
Myris Therapeutics emerges from stealth to announce new name and strategic focus Proprietary polymer chemistry enables ultra-high drug to antibody ratios of 50 - 100 and new chemical space for precision targeted ADC payloads PITTSBURGH, Feb. 20,...
BioHybrid Solutions Holdings, Inc. Announces Expansion of its Drug Development Leadership
Pittsburgh, PA. June 02, 2023 Biohybrid Solutions Holdings, Inc. (BHS), is a biotechnology company using advanced polymer technologies to address outstanding challenges in the development of biologic drugs. BHS’ NanoArmor® technology balances...
BioHybrid Solutions Holdings, Inc. Appoints Mark Murcko as Board Member
Pittsburgh, PA. August 09, 2022 We are excited to announce the appointment of Mark Murcko, Ph.D., as our newest Board Member. Mark brings over three decades of industry experience, having been at the center of many transformational biotech efforts...